HOME >> MEDICINE >> NEWS
Medical experts unite to raise awareness of risk, threat of blood clots

Council for Leadership on Thrombosis Awareness and Management formed to advance prevention and treatment of overlooked public health problem

TARRYTOWN, NY, February 14, 2002 -- Calling deep-vein thrombosis (DVT), or blood clots, an underestimated public health problem, the Council for Leadership On Thrombosis (CLOT) Awareness and Management announced its formation today to raise awareness, advance prevention and treatment, and reduce the dangers of DVT, a potentially life-threatening condition that affects approximately 2 million Americans per year.

Comprised of medical experts representing various specialties and affiliated with leading U.S. institutions, the Council plans to target both health care professionals and the general public with such major initiatives as a national DVT FREE screening program of 7,500 patients at more than 200 hospitals, and the ClotAlert Resource Center, a multifaceted campaign to educate consumers, physicians and health professionals about the risk factors and symptoms of DVT.

Deep-vein thrombosis represents one of the most commonly occurring and serious medical conditions, yet it has never received the same attention as heart attack or stroke, said Samuel Z. Goldhaber, MD, director of Venous Thromboembolism Research Group and Cardiac Centers Anticoagulation Service at Brigham and Womens Hospital in Boston, Mass., associate professor of medicine, Harvard Medical School, and co-chair of the Council for Leadership On Thrombosis Awareness and Management. The public is not nearly as educated about the potential health risk of DVT, nor is the public aware of the symptoms associated with blood clots. Our mission as a Council is to raise awareness of DVT so the public can recognize the symptoms and urgently seek medical help.

This is the first time that DVT has been portrayed as a true public health problem, said Victor Tapson, MD, associate professor, Division of Pulmonary Medicine, Department of
'"/>

Contact: Kristen Supchak
kristens@mcspr.com
908-234-9900
MCS
14-Feb-2002


Page: 1 2 3

Related medicine news :

1. Medically supervised drug injection facilities safer for users
2. Medical molecules designed to respond to visible light that can penetrate tissue
3. Philanthropist Paul F. Glenn launches labs for aging research at Harvard Medical School
4. UCLA Medical Center becomes first hospital to introduce remote presence robots in ICU
5. New data on Orqis Medicals Cancion CRS to be reported at ACC
6. Medical technologies may hinder rather than help newborn survival
7. Medical meeting to feature research findings and disease prevention and health promotion sessions
8. LA BioMed Medical/Research briefs January 2005
9. Medical negligence system is secretive, unaccountable and unregulated
10. Dartmouth Medical School receives $1.6 million in AIDS funding
11. LA BioMed Medical/Research Briefs December 2004

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Medical experts unite raise awareness risk threat blood clots

(Date:8/1/2015)... (PRWEB) , ... August 01, 2015 , ... ... Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & Wellness ... into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical Therapy ...
(Date:8/1/2015)... ... August 01, 2015 , ... Lume Wellness creators Alex, Robert, and Sam have ... the Apple AppStore. , The app is designed to track various metrics of ... tool to view personal health and use this information for positive behavior modification. Lume ...
(Date:8/1/2015)... ... ... “ reTXT ” was featured on NewsWatch as part of its monthly AppWatch, ... iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted ... any message including ones already sent. , While text messaging has more features than ...
(Date:7/31/2015)... ... 31, 2015 , ... That’s right, the STASH awards have ... The Significant Technological Achievements in Secretive Horticulture (or STASH) Awards, featured in High ... that have stood the test of time. These include lighting products, organic and ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... When the ... stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) zoysia . ... in process. , To commemorate introduction of this new type of sod, Super-Sod is ...
Breaking Medicine News(10 mins):Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2
(Date:7/30/2015)... CHENGDU, China , July 30, 2015 ... "Company"), a pharmaceutical company that specializes in the patented ... active pharmaceutical ingredients (API), provided updates regarding the notice ... MKT LLC (the "Exchange") indicating that the Company was ... set forth in Sections 134 and 1101 of the ...
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
(Date:7/30/2015)... , July 30, 2015 ... latest report titled, "Continuous Glucose Monitoring Systems Market: Global ... to the report, the global continuous glucose monitoring systems ... and is expected to reach US$ 788.4 Mn by ... period, 2015 to 2020. Global continuous glucose ...
Breaking Medicine Technology:TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4
Cached News: